Experimental group:hUC - MSC PLEB001 treatment

2 trials

Sponsors

The First Medical Center of the PLA General Hospital

Conditions

Steroid-Refractory acute Graft versus Host Disease (aGVHD)Steroid-Refractory acute graft versus host disease (aGVHD)

Phase 2

To evaluate the efficacy and safety of hUC-MSC PLEB001 in patients with grade II to IV steroid-refractory aGVHD

Active, not recruitingChiCTR2000035740

The First Medical Center of the PLA General HospitalSteroid-Refractory acute graft versus host disease (aGVHD)

Start: 2020-08-08Updated: 2024-05-06

Phase 3

To evaluate the therapeutic effect of HUC-MSC PLEB001 in Steroid-Refractory acute graft versus host disease (aGVHD)

RecruitingChiCTR2300073965

The First Medical Center of the PLA General HospitalSteroid-Refractory acute Graft versus Host Disease (aGVHD)

Start: 2023-02-23Updated: 2023-07-30

Related Papers

Mesenchymal stromal cells as add-on therapy to anti-CD25 antibodies for treating gastrointestinal-involved steroid-refractory acute graft-versus-host disease: a multicenter, single-arm, pivotal clinical trial

Stem Cell Research & Therapy2026-03-24

Efficacy and safety of human umbilical cord-derived mesenchymal stem cells versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease: a multicentre, randomized, double-blind, phase 2 trial.

2024-11-2511 citations

P1276: HUMAN UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELL FOR THE TREATMENT OF STEROID-REFRACTORY AGVHD: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND PHASE 2 TRIAL

HemaSphere2023-08-01

Efficacy and safety of human umbilical cord-derived mesenchymal stem cells (hUC-MSC PLEB001) for the treatment of grade II–IV steroid-refractory acute graft-versus-host disease: a study protocol for a multicenter, randomized, double-blind, placebo-controlled, phase II trial

Trials2023-05-037 citations